Blood Cancer

As the 10th most common cancer in the United States, leukemia will affect up to 2 percent of Americans at some point in their lifetime.

Pepaxto was deemed to have ‘potential detriment in overall survival’ in patients in a phase 3 trial, prompting the FDA’s decision.

Clinical trial findings showed both treatments could reduce pain from vaso-occlusive events, hallmarks of sickle cell disease.

“It’s not about winning, it’s about what can be done through the collective efforts of a team,” Jennifer Taggart told me when we met in Hauppauge Long Island recently.

As the 10th most common cancer in the United States, leukemia will affect up to 2 percent of Americans at some point in their lifetime.

Pepaxto was deemed to have ‘potential detriment in overall survival’ in patients in a phase 3 trial, prompting the FDA’s decision.

Clinical trial findings showed both treatments could reduce pain from vaso-occlusive events, hallmarks of sickle cell disease.

“It’s not about winning, it’s about what can be done through the collective efforts of a team,” Jennifer Taggart told me when we met in Hauppauge Long Island recently.